Plasma levels of C-reactive protein after coronary stent implantation

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Inflammation Research

Background:

• Coronary stent implantation is a common procedure for treating coronary artery disease.
• Angiographic restenosis remains a significant complication following stent placement.
• Inflammation is implicated in the development of restenosis, but its precise role and modulation by therapies are not fully understood.

Purpose of the Study:

• To investigate the association between inflammation, measured by C-reactive protein (CRP) levels, and angiographic restenosis after coronary stent implantation.
• To evaluate the influence of different antithrombotic and antiplatelet strategies on inflammatory markers and restenosis rates.

Main Methods:

• An open randomized trial involving 40 patients undergoing elective coronary stent implantation.
• Patients received aspirin plus either ticlopidine or phenprocoumon with dipyridamole.
• Plasma CRP levels were measured serially up to 120 hours post-implantation and at 6 months.
• Angiographic restenosis was assessed at 6 months.

Main Results:

• CRP levels significantly increased after stent implantation (P<0.0001).
• Neither ticlopidine nor phenprocoumon/dipyridamole regimens affected CRP levels or restenosis rates (P=0.51 and P=0.48, respectively).
• Higher CRP levels were observed in patients with complex lesion types (C vs. A/B, P=0.035).
• Patients with restenosis exhibited significantly higher CRP levels, with peak levels occurring later (P=0.038).

Conclusions:

• Elevated CRP levels persisting beyond 96 hours post-stent implantation may signify a sustained inflammatory reaction.
• This prolonged inflammation could be a causal factor in the pathophysiology of coronary restenosis.
• Current antithrombotic and antiplatelet strategies did not significantly impact CRP levels or restenosis in this cohort.